Similar studies were also conducted by Martinetti et al. [45], who showed that osteoprotegerin (OPG) and osteopontin (OPN) appear to be useful predictors of the outcome of skeletal disease and elevated OPN values may be associated with short survival in advanced breast cancer patients. This evidence concerns the gene SPP1 and breast carcinoma.